Stockscreener 앱 받기
13.63
2.01%
-0.28
시간 외 거래:
13.62
-0.01
-0.07%
전일 마감가:
$13.91
열려 있는:
$13.95
하루 거래량:
217.75K
Relative Volume:
0.70
시가총액:
$335.93M
수익:
$47.26M
순이익/손실:
$-58.48M
주가수익비율:
-6.4905
EPS:
-2.1
순현금흐름:
$-40.45M
1주 성능:
-13.90%
1개월 성능:
+43.62%
6개월 성능:
+64.41%
1년 성능:
-22.99%
1일 변동 폭
$13.39
$14.19
1주일 범위
$13.39
$15.91
52주 변동 폭
$6.40
$33.13
Cvrx Inc Stock (CVRX) Company Profile
명칭
Cvrx Inc
전화
(763) 416-2850
주소
9201 WEST BROADWAY AVENUE, MINNEAPOLIS
CVRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| CVRX | 13.63 | 335.93M | 47.26M | -58.48M | -40.45M | -2.10 |
| ABT | 117.36 | 202.64B | 41.22B | 5.77B | 6.49B | 2.94 |
| SYK | 389.40 | 150.72B | 21.97B | 3.59B | 3.21B | 6.74 |
| BSX | 90.45 | 133.82B | 15.91B | 1.79B | 1.89B | 0.82 |
| MDT | 87.59 | 112.98B | 32.58B | 3.93B | 5.15B | 2.71 |
| EW | 69.89 | 40.52B | 6.60B | 4.16B | 490.10M | 2.34 |
Cvrx Inc Stock (CVRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-09-10 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-07-11 | 재확인 | Lake Street | Buy |
| 2024-05-01 | 재개 | Craig Hallum | Buy |
| 2024-05-01 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-05-01 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-01-31 | 개시 | Lake Street | Buy |
| 2022-07-18 | 개시 | Craig Hallum | Buy |
| 2021-07-26 | 개시 | Canaccord Genuity | Buy |
| 2021-07-26 | 개시 | Piper Sandler | Overweight |
| 2021-07-26 | 개시 | William Blair | Outperform |
모두보기
Cvrx Inc 주식(CVRX)의 최신 뉴스
CVRx, Inc. (NASDAQ:CVRX) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
CVRx’s Barostim Gains New CPT Codes - MPO-mag
(CVRX) Long Term Investment Analysis - Stock Traders Daily
International Assets Investment Management LLC Makes New Investment in CVRx, Inc. (NASDAQ:CVRX) - MarketBeat
CVRx: Impressive Top-Line Growth Seems Priced In - Seeking Alpha
Cantor Fitzgerald Initiates Coverage of CVRx (CVRX) with Overweight Recommendation - MSN
CVRx (NASDAQ:CVRX) Stock Price Expected to Rise, Craig Hallum Analyst Says - MarketBeat
CVRx earns Medicare win for Barostim procedure - Mass Device
CVRx gains CMS payment classification for Barostim - Investing.com
CVRx Announces Positive Outpatient Payment for Barostim Procedure in 2025 - GlobeNewswire
CVRx, Inc. (NASDAQ:CVRX) Position Decreased by Emerald Advisers LLC - MarketBeat
CVRx, Inc. (NASDAQ:CVRX) Q3 2024 Earnings Call Transcript - MSN
FY2024 EPS Estimates for CVRx Lowered by Cantor Fitzgerald - MarketBeat
Analyst Estimates: Here's What Brokers Think Of CVRx, Inc. (NASDAQ:CVRX) After Its Third-Quarter Report - Simply Wall St
CVRx, Inc. (NASDAQ:CVRX) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year - Yahoo Finance
CVRx (CVRX) Reports Q3 Loss, Tops Revenue Estimates - MSN
How the (CVRX) price action is used to our Advantage - Stock Traders Daily
Canaccord lifts CVRx stock target, keeps buy rating on strong Q3 results By Investing.com - Investing.com South Africa
Canaccord lifts CVRx stock target, keeps buy rating on strong Q3 results - Investing.com
Earnings call: CVRx reports robust Q3 growth, eyes future reimbursement wins - Investing.com India
CVRx (NASDAQ:CVRX) Given New $15.00 Price Target at Lake Street Capital - MarketBeat
CVRx (NASDAQ:CVRX) Given "Overweight" Rating at Piper Sandler - MarketBeat
CVRx Reports Strong Revenue Growth in Q3 2024 - TipRanks
CVRx earnings missed by $0.10, revenue topped estimates - Investing.com Canada
CVRx: Q3 Earnings Snapshot - The Advocate
CVRx Reports Third Quarter 2024 Financial and Operating Results - GlobeNewswire
CVRx Inc Q3 2024 Earnings: Revenue Hits $13.4M, EPS at -$0.57, S - GuruFocus.com
CVRx, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
CVRx (CVRX) Price Target Increased by 10.54% to 33.15 - MSN
CVRx's SWOT analysis: barostim maker's stock faces reimbursement hurdles By Investing.com - Investing.com South Africa
CVRx's SWOT analysis: barostim maker's stock faces reimbursement hurdles - Investing.com India
CVRx (NASDAQ:CVRX) Receives Overweight Rating from Cantor Fitzgerald - MarketBeat
CVRx, Inc. (NASDAQ:CVRX) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
Cantor Fitzgerald stays positive on CVRx, reaffirms $14 stock PT after survey - Investing.com
CVRx, Inc. (NASDAQ:CVRX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
CVRx (CVRX) Set to Announce Earnings on Tuesday - MarketBeat
CVRx, Inc. Shares Surge Following Key Heart Failure Treatment Approval - Stocks Telegraph
CVRx (CVRX) Soars 17.2%: Is Further Upside Left in the Stock? - Yahoo Finance
Canaccord maintains Buy rating on CVRx stock - Investing.com
Canaccord maintains Buy rating on CVRx stock By Investing.com - Investing.com UK
CVRx announces new CPT Category I codes for Barostim heart failure therapy - Yahoo Finance
AMA approves new codes for heart failure therapy By Investing.com - Investing.com Australia
CVRx announces new CPT® Category I codes for Barostim - The Manila Times
AMA approves new codes for heart failure therapy - Investing.com
Cvrx Inc (CVRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.38%
0.43%
자본화:
|
볼륨(24시간):